Landec Corporation (LNDC)
Stock Price Chart
Key Info
| Market Cap | 301.16M |
| Revenue (ttm) | 587.01M |
| Net Income (ttm) | -23.30M |
| Shares Out | 29.18M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | 43.86 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 7, 2020 |
| Last Price | $10.32 |
| Previous Close | $10.29 |
| Change ($) | 0.03 |
| Change (%) | 0.29% |
| Day's Open | 10.25 |
| Day's Range | 9.71 - 10.42 |
| Day's Volume | 89,614 |
| 52-Week Range | 7.48 - 12.46 |
More Stats
| Market Cap | 301.16M |
| Enterprise Value | 503.97M |
| Earnings Date (est) | Aug 11, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 29.18M |
| Float | 22.63M |
| EPS (basic) | -0.79 |
| EPS (diluted) | -0.80 |
| FCF / Share | -1.27 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.22M |
| Short Ratio | 6.11 |
| Short % of Float | 6.16% |
| Beta | 1.03 |
| PE Ratio | n/a |
| Forward PE | 43.86 |
| P/FCF Ratio | n/a |
| PS Ratio | 0.51 |
| PB Ratio | 1.11 |
| Revenue | 587.01M |
| Operating Income | -21.74M |
| Net Income | -23.30M |
| Free Cash Flow | -37.02M |
| Net Cash | -202.81M |
| Net Cash / Share | -6.95 |
| Gross Margin | 13.80% |
| Operating Margin | -3.70% |
| Profit Margin | -4.00% |
| FCF Margin | -6.31% |
| ROA | -0.71% |
| ROE | -8.76% |
| ROIC | -4.70% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 558 | 524 | 470 | 477 | 539 | 477 | 442 | 318 | 277 | 238 |
| Revenue Growth | 6.36% | 11.59% | -1.5% | -11.56% | 13.1% | 7.95% | 39.1% | 14.75% | 16.16% | - |
| Gross Profit | 81.00 | 78.34 | 79.21 | 66.78 | 65.41 | 62.56 | 62.76 | 52.14 | 46.70 | 33.77 |
| Operating Income | 5.48 | 13.59 | 14.67 | -20.63 | 18.46 | 20.19 | 24.87 | 14.58 | 8.03 | 7.98 |
| Net Income | 0.41 | 24.83 | 10.59 | -11.64 | 13.54 | 19.15 | 22.59 | 12.70 | 3.92 | 3.98 |
| Shares Outstanding | 28.36 | 27.54 | 27.28 | 27.04 | 26.88 | 26.63 | 25.83 | 25.85 | 26.40 | 26.38 |
| Earnings Per Share | 0.01 | 0.89 | 0.38 | -0.43 | 0.50 | 0.71 | 0.85 | 0.49 | 0.15 | 0.15 |
| EPS Growth | -98.88% | 134.21% | - | - | -29.58% | -16.47% | 73.47% | 226.67% | 0% | - |
| Operating Cash Flow | 16.02 | 19.78 | 29.84 | 20.76 | 26.62 | 21.05 | 21.23 | 22.18 | 14.47 | 7.48 |
| Capital Expenditures | -44.47 | -33.49 | -22.92 | -39.57 | -16.44 | -14.89 | -8.88 | -5.37 | -6.68 | -5.19 |
| Free Cash Flow | -28.45 | -13.71 | 6.92 | -18.81 | 10.18 | 6.16 | 12.35 | 16.81 | 7.79 | 2.29 |
| Cash & Equivalents | 1.08 | 2.90 | 6.00 | 9.89 | 14.13 | 14.24 | 15.26 | 22.18 | 36.26 | 48.24 |
| Total Debt | 153 | 72.94 | 53.97 | 61.15 | 42.52 | 34.37 | 44.31 | 58.98 | 19.83 | 23.77 |
| Net Cash / Debt | -152 | -70.04 | -47.97 | -51.26 | -28.39 | -20.13 | -29.04 | -36.81 | 16.43 | 24.47 |
| Assets | 519 | 405 | 359 | 343 | 346 | 314 | 291 | 278 | 206 | 200 |
| Liabilities | 249 | 152 | 130 | 130 | 126 | 109 | 111 | 126 | 68.59 | 67.72 |
| Book Value | 270 | 253 | 227 | 211 | 218 | 203 | 179 | 150 | 136 | 131 |
Company Profile
Company Details
| Full Name | Landec Corporation |
| Country | United States |
| Employees | 736 |
| CEO | Albert D. Bolles |
Stock Information
| Ticker Symbol | LNDC |
| Stock Exchange | NASDAQ |
| Sector | Consumer Defensive |
| Industry | Packaged Foods |
| Unique Identifier | NASDAQ: LNDC |
| IPO Date | February 15, 1996 |
Description
Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets. It operates through Curation Foods and Lifecore segments. The Curation Foods segment engages in processing, marketing, and selling of vegetable-based salads, and fresh-cut and whole vegetable products primarily under the Eat Smart brand, O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products, as well as various private labels. It serves retail grocery chains, club stores, and food service operators. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology transfer, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. It sells its products directly to partners in the medical device and pharmaceutical markets. The company was founded in 1986 and is headquartered in Santa Clara, California.